None listed
Conditions
Interventions
Experimental group:Modified Shenling Baizhu Powder
Control group:Clostridium Butyricum and Bifidobacterium Capsule
Sponsors
The First Affiliated Hospital of Anhui University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18~70 years; 2. Patients with renal failure who underwent CAPD and had stable dialysis for more than 6 months; 3. Conform to the syndrome differentiation standard of spleen deficiency and blood stasis syndrome in Chinese medicine; 4. Meet the diagnostic criteria of functional gastrointestinal diseases; 5. The patient agreed to join the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients receiving hemodialysis treatment simultaneously; 2. Severe primary diseases such as active malignant tumors, decompensated cirrhosis or hematopoietic system; 3. Abdominal infection occurred within 3 months before the collection of indicators; 4. Severe arrhythmias, severe heart failure, NYHA grade ? or above (New York Heart Association grade ? or ? evidence), or myocardial infarction or cerebrovascular events in the 3 months prior to inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pepsinogen I;Pepsinogen ?;Gastrin;Motilin;Somatostatin;Cholecystokinin;Vasoactive intestinal peptide;Pancreatic polypeptide;Intestinal flora; | — |
Secondary
| Measure | Time frame |
|---|---|
| Albumin;Leptin;Interleukin 10;Interleukin 18; | — |
Countries
China
Contacts
Public ContactLyu Yong
Department of Nephrology, the First Affiliated Hospital of Anhui University of Chinese Medicine
Outcome results
None listed